Literature DB >> 20479398

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Barbara S Paugh1, Chunxu Qu, Chris Jones, Zhaoli Liu, Martyna Adamowicz-Brice, Junyuan Zhang, Dorine A Bax, Beth Coyle, Jennifer Barrow, Darren Hargrave, James Lowe, Amar Gajjar, Wei Zhao, Alberto Broniscer, David W Ellison, Richard G Grundy, Suzanne J Baker.   

Abstract

PURPOSE: To define copy number alterations and gene expression signatures underlying pediatric high-grade glioma (HGG). PATIENTS AND METHODS: We conducted a high-resolution analysis of genomic imbalances in 78 de novo pediatric HGGs, including seven diffuse intrinsic pontine gliomas, and 10 HGGs arising in children who received cranial irradiation for a previous cancer using single nucleotide polymorphism microarray analysis. Gene expression was analyzed with gene expression microarrays for 53 tumors. Results were compared with publicly available data from adult tumors.
RESULTS: Significant differences in copy number alterations distinguish childhood and adult glioblastoma. PDGFRA was the predominant target of focal amplification in childhood HGG, including diffuse intrinsic pontine gliomas, and gene expression analyses supported an important role for deregulated PDGFRalpha signaling in pediatric HGG. No IDH1 hotspot mutations were found in pediatric tumors, highlighting molecular differences with adult secondary glioblastoma. Pediatric and adult glioblastomas were clearly distinguished by frequent gain of chromosome 1q (30% v 9%, respectively) and lower frequency of chromosome 7 gain (13% v 74%, respectively) and 10q loss (35% v 80%, respectively). PDGFRA amplification and 1q gain occurred at significantly higher frequency in irradiation-induced tumors, suggesting that these are initiating events in childhood gliomagenesis. A subset of pediatric HGGs showed minimal copy number changes.
CONCLUSION: Integrated molecular profiling showed substantial differences in the molecular features underlying pediatric and adult HGG, indicating that findings in adult tumors cannot be simply extrapolated to younger patients. PDGFRalpha may be a useful target for pediatric HGG, including diffuse pontine gliomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479398      PMCID: PMC2903336          DOI: 10.1200/JCO.2009.26.7252

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  55 in total

1.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Authors:  S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.

Authors:  M Bredel; I F Pollack; R L Hamilton; C D James
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

3.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Authors:  Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay
Journal:  J Neurosurg       Date:  2006-11       Impact factor: 5.115

4.  PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling.

Authors:  Erica L Jackson; Jose Manuel Garcia-Verdugo; Sara Gil-Perotin; Monica Roy; Alfredo Quinones-Hinojosa; Scott VandenBerg; Arturo Alvarez-Buylla
Journal:  Neuron       Date:  2006-07-20       Impact factor: 17.173

5.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

6.  Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital.

Authors:  A W Walter; M L Hancock; C H Pui; M M Hudson; J S Ochs; G K Rivera; C B Pratt; J M Boyett; L E Kun
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

7.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.

Authors:  E C Holland; W P Hively; R A DePinho; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

8.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

9.  Genetic abnormalities detected in ependymomas by comparative genomic hybridisation.

Authors:  M Carter; J Nicholson; F Ross; J Crolla; R Allibone; V Balaji; R Perry; D Walker; R Gilbertson; D W Ellison
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

10.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

View more
  296 in total

1.  Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.

Authors:  Barbara S Paugh; Alberto Broniscer; Chunxu Qu; Claudia P Miller; Junyuan Zhang; Ruth G Tatevossian; James M Olson; J Russell Geyer; Susan N Chi; Nasjla Saba da Silva; Arzu Onar-Thomas; Justin N Baker; Amar Gajjar; David W Ellison; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Evidence for and against regional differences in neural stem and progenitor cells of the CNS.

Authors:  Oren J Becher; Eric C Holland
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

3.  Pediatric and adult gliomas: how different are they?

Authors:  Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2010-12       Impact factor: 12.300

Review 4.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 5.  Malignant transformation in pediatric spinal intramedullary tumors: case-based update.

Authors:  E Winograd; N Pencovich; M Yalon; D Soffer; L Beni-Adani; S Constantini
Journal:  Childs Nerv Syst       Date:  2012-07-10       Impact factor: 1.475

6.  Human pontine glioma cells can induce murine tumors.

Authors:  Viola Caretti; A Charlotte P Sewing; Tonny Lagerweij; Pepijn Schellen; Marianna Bugiani; Marc H A Jansen; Dannis G van Vuurden; Anna C Navis; Ilona Horsman; W Peter Vandertop; David P Noske; Pieter Wesseling; Gertjan J L Kaspers; Javad Nazarian; Hannes Vogel; Esther Hulleman; Michelle Monje; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2014-04-29       Impact factor: 17.088

Review 7.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 8.  Molecular markers in pediatric neuro-oncology.

Authors:  Koichi Ichimura; Ryo Nishikawa; Masao Matsutani
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma.

Authors:  Christopher L Tinkle; Elizabeth C Duncan; Mikhail Doubrovin; Yuanyuan Han; Yimei Li; Hyun Kim; Alberto Broniscer; Scott E Snyder; Thomas E Merchant; Barry L Shulkin
Journal:  J Nucl Med       Date:  2018-08-02       Impact factor: 10.057

Review 10.  Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.

Authors:  Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.